IgG Subclass Switch in Volunteers Repeatedly Immunized with the Full-Length <em>Plasmodium falciparum</em> Merozoite Surface Protein 1 (MSP1)

Vaccines are highly effective tools against infectious diseases and are also considered necessary in the fight against malaria. Vaccine-induced immunity is frequently mediated by antibodies. We have recently conducted a first-in-human clinical trial featuring SumayaVac-1, a malaria vaccine based on the recombinant, full-length merozoite surface protein 1 (MSP1(FL)) formulated with GLA-SE as an adjuvant. Vaccination with MSP1(FL) was safe and elicited sustainable IgG antibody titers that …